PubMed Health⌕ Search

Biomedical subjects

R Anton

Publications and source records attributed to R Anton.

At least 73 records · Page 4Linked to original sources
PubMed1990

Cocaine abuse among schizophrenic patients.

Initial studies have indicated that stimulant abuse is prevalent among schizophrenic persons. To assess the phenomenon of cocaine abuse by patients with schizophrenia, 17 male cocaine-abusing schizophrenic patients were compared with 22 male schizophrenic patients who did not use cocaine. The cocaine-abusing subjects had been hospitalized more frequently, were more likely to be of the paranoid subtype, and were more likely to be depressed at the time of interview. It appears that cocaine abuse may influence both the psychopathologic presentation of schizophrenic patients and the intensity of care that they require.

Adult↗
PubMed1989

Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract.

Ginkgo biloba extract is known to be efficient in diseases associated with free radical generation. The purpose of this work was to study, under in vitro conditions, the action of Ginkgo biloba extract (Gbe) against superoxide anion (O2-.), which is directly or indirectly implicated in cell damage. Gbe appears to have both an O2-. scavenging effect and also a superoxide dismutase activity. Its antiradical effect was demonstrated by low temperature electron spin resonance and in a non-enzymatic system (phenazine methosulfate-NADH), and its enzymatic activity was shown by polarographic determination.

Animals↗
PubMed1989

Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder.

Urinary free cortisol (UFC) excretion in 31 patients with major depression is directly compared to UFC levels in 65 patients with panic disorder and 36 controls. Patients with depression demonstrated significantly higher UFC excretion [43 +/- 37 micrograms/g creatinine (cr)] than patients with panic disorder (29 +/- 13 micrograms/g-cr) or controls (22 +/- 10 micrograms/g-cr) (F = 8.5, df = 129, p less than 0.001). Panic patients with a secondary depression (35 +/- 17 micrograms/g-cr) or those with agoraphobia (34 +/- 14 micrograms/g-cr) had UFC levels that were in-between patients with primary major depression and panic patients without these complications (25 +/- 11 micrograms/g-cr). These findings support the hypothesis that patients with major depression, whether primary or secondary, and those with agoraphobia excrete more UFC than patients with uncomplicated panic disorder. This occurs despite the fact that panic disorder might also be expected to raise the stress-responsive hormone cortisol.

Adult↗
PubMed1989

Effect of recombinant human growth hormone therapy on bone and clinical parameters in girls with Turner's syndrome. The Spanish Collaborative Group.

Forty-eight girls with Turner's syndrome were assigned to one of three treatments; recombinant human growth hormone (rhGH) alone, rhGH plus oxandrolone, and rhGH plus ethinyloestradiol. Treatment with rhGH alone or in combination with oxandrolone induced catch-up growth. Older girls treated with rhGH plus ethinyloestradiol showed less marked improvement. The gain in height was associated with a gain in bone diameter and cortical thickness (reflecting increased bone mass). There was a rapid loss of subcutaneous fat. These effects of growth hormone are similar to those observed in patients with growth hormone deficiency.

Adolescent↗
PubMed1989

Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal.

Of 86 alcoholic men with severe alcohol withdrawal who began a double-blind controlled study comparing carbamazepine, 800 mg/day, to oxazepam, 120 mg/day, 66 (carbamazepine, N = 32; oxazepam, N = 34) completed the 7-day trial. In general, the drugs were found to be equally efficacious in treating the withdrawal syndrome and not significantly different with respect to side effects. The subjects taking oxazepam had an increase in global psychological distress from day 3 to day 7, and those taking carbamazepine exhibited a decline. The study suggests that carbamazepine is as effective and safe as benzodiazepine treatment for alcohol withdrawal.

Adult↗
PubMed1986

Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.

Amentoflavone hexaacetate (AmAc) was synthesized from natural amentoflavone (Am), a biflavonoid extracted from Viburnum lantana L. Am does not inhibit aggregation of intact platelets up to a concentration of 100 microM but inhibits human platelet cAMP phosphodiesterase (IC50 = 22.0 microM). AmAc is a potent inhibitor of the aggregation of washed human platelets induced by ADP (IC50 = 2.3 microM) or collagen (IC50 = 4.7 microM). AmAc inhibits crude (IC50 = 8.6 microM) or partially purified (IC50 = 42.2 microM) human platelet cAMP phosphodiesterase. In the presence of prostaglandin E1, AmAc (10 microM) induces a 3.7-fold increase in total platelet cAMP. The characteristics of this action suggest a role for cAMP in the mechanism of action of AmAc. The incubation of AmAc with intact platelets for 5 min is necessary for its activity.

3',5'-Cyclic-AMP Phosphodiesterases↗
PubMed1986

[Traditional medicine in the Central Plateau of Haiti. 1. Study of the traditional therapeutic system in a rural socio-cultural area].

An ethnomedical and ethnopharmacological research on the traditional use of plants to cure human diseases was carried out in the Thomonde area located in the Central Plateau of Haiti. The use of medicinal plants is widespread among the rural population and is often the first treatment utilized. An ethnomedical approach to the Haitian traditional therapeutic system and popular beliefs is made. The percentage home remedies used as first treatment against 38 diseases was determined by means of an investigation performed on a quantitative scale.

Cultural Characteristics↗
PubMed1986

[Traditional medicine in the Central Plateau of Haiti. 2. Ethnopharmacologic inventory].

An ethnomedical and ethnopharmacological research on the traditional use of plants to cure human diseases was carried out in the Thomonde area located in the Central Plateau of Haïti. Part 1 of this publication was an ethnomedical study of the traditional folk therapy system. In this second part, we list 161 local plants, distributed in 64 botanical families, currently used for treating 38 common diseases. These 161 species were collected and identified. Their latin names, local names, local medicinal uses, the used part of the plant and the form of remedy are described.

Demography↗
PubMed1985

Inhalation of U aerosols from UO2 fuel element fabrication.

Publication No. 30 of the International Commission on Radiological Protection (ICRP) assigns the uranium oxides UO2 and U3O8 to transportability class Y, i.e. the half-life of these compounds in the lungs is about 500 days. This assignment seemed not to be in accordance with our experience resulting from incorporation surveillance during UO2 fuel element fabrication. Persons who worked in atmospheres containing UO2 aerosols with activity concentrations significantly above the derived air concentrations (DAC) for class Y U showed much lower activity in the lungs than would be expected according to the ICRP. To understand this discrepancy, aerosol concentrations and aerosol particle-size distributions at work places with the possibility of UO2 incorporation, the activity of urine and feces and the lung activity of persons working at these places were measured in an investigation program. The results are only consistent with the ICRP lung model if one uses a measured biological half-life in the lungs of 109 days and a measured AMAD of 8.2 micron instead of the ICRP standard assumptions of 500 days and 1.0 micron, respectively. ICRP Publication No. 30 recommends application of specific parameters for health physics instead of standard model values. For the special conditions in our UO2 fuel fabrication plant we therefore derive limits of air concentrations, lung activities and fecal and urinary activity concentrations by applying our measured particle-size and lung-retention parameters to the ICRP model. Our special derived limits in comparison to class Y limits for U after ICRP Publication No. 30 for a 1-micron AMAD and 500-day half-life (in brackets) are: (a) annual limit of intake: 6 X 10(4) Bq/y (1 X 10(3) Bq/y); (b) derived air concentration: 20 Bq/m3 (0.6 Bq/m3); (c) derived lung activity: 1.6 X 10(3) Bq; (d) derived fecal activity: 14 Bq/day; and (e) derived urine activity: 8.9 Bq/day. The committed dose equivalents calculated from our measured data and from our modified derived limits proved consistent for the different incorporation control methods (determination of air concentration, lung, fecal or urinary activity). The authors recommend that in accordance with ICRP Publication No. 30, the national rules and regulations on activity incorporation provide the possibility to derive special limits from specific work-place parameters such as particle-size distributions and biological half-lives, thus supplementing the ICRP standard assumptions of 1 micron AMAD and biological half-lives of 0.5 days for class D, 50 days for class W and 500 days for class Y compounds.

Adult↗